

CV Michael Lübbert

1) General Information

Name: Lübbert, Michael, Prof. Dr. med.
Born: 13.06.1957
Gender: male
Address: Department of Medicine, Division of Hematology/Oncology
University of Freiburg Medical Center
Hugstetter Strasse 55, 79106 Freiburg
Telephone: +49 761 270 32790
E-Mail: michael.luebbert@uniklinik-freiburg.de
Position: Professor (Apl.)
Social status: married

2) University Education

10/1976-07/1983 Study of Psychology, University of Hamburg, degree "Diplom",
tutor: Dr F. Teegen, Div. Clinical Psychology, Dept. Psychology
04/1978-06/1985 Study of Medicine, University of Hamburg, tutor: Prof. J. Kruppa,
Dept. Molecular Biology

3) Scientific Education and Appointments

1995 Habilitation in Internal Medicine, University of Freiburg

4) Professional Career

03/1986-10/1988 Research fellow at UCLA School of Medicine, Division of Hematology/Oncology,
Los Angeles, USA, tutor: Prof. H. P. Koefler
10/1988-10/1990 Senior Research Fellow, University of Mainz, University of Freiburg Medical Center,
Department of Hematology/Oncology, tutor: Prof. R. Mertelsmann
10/1990-03/1996 Clinical Training in Internal Medicine and Hematology/Oncology, University of Freiburg
Medical Center, tutor: Prof. R. Mertelsmann
06/1996 Appointment to Attending Physician, University of Freiburg Medical Center, Department
of Hematology/Oncology
08/2003 Appointment "Außerplanmäßiger Professor"
2003-2006 Managing Associate Director, Dept. Hematology/Oncology ,
University of Freiburg Medical Center
2005 Appointment: Coordinator, Leukemia and Preleukemia Center, Comprehensive Cancer
Center Freiburg

5) Other Qualifications

Scientific honours

2006-2012 Secretary, EORTC Leukemia Cooperative Group
2008-2019 Coordinator, DFG Consortium SPP 1463 "Epigenetics of myelopoiesis"
(together with Prof. Dr. Christoph Plass, Heidelberg)
since 2010 Chairman, Süddeutsche Hämoblastose-Gruppe (SHG)
2014 Editor (with Peter A. Jones): "Epigenetic Therapy of Cancer" (Springer)
since 2017 Coordinator, DFG Consortium FOR 2674 "Aging-related epigenetic remodelling in AML"
(together with Prof. Dr. Christoph Plass, Heidelberg)
since 2018 Chairman, EORTC Leukemia Cooperative Group

Presentations and seminars

150+ presentations as invited speaker at international meetings and research institutions.

Referee activities

Referee duties for German Science Foundation (DFG), German Cancer Aid (Krebshilfe), Schweizer Krebsliga,
Italian Association for Cancer Research, Cancer Research UK, Nationalfonds Österreich, Dutch Cancer
Society, National Heart, Blood and Lung Institute Study Section.

Referee duties for major journals such as Science, Cell, Cell Reports, JCO, Blood, Cancer Research,
Oncogene, Leukemia, PLoS ONE, Haematologica, Leukemia Research, among others.

Ten Publications

Blagitko-Dorfs N., Schlosser P., Greve G., Pfeifer D., Meier R., Baude A., Brocks D., Plass C. and **Lübbert M.** (2019) Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. **Leukemia** 33, 945-956.

Becker H., Greve G., Kataoka K., Mallm J.P., Duque-Afonso J., Ma T., Niemöller C., Pantic M., Duyster J., Cleary M.L., Schüler J., Rippe K., Ogawa S. and **Lübbert M.** (2019) Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia. **Blood Adv** 3, 761–765.

Greve G., Schiffmann I. and **Lübbert M.** (2015) Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-*trans* retinoic acid. **J Cancer Res Clin Oncol** doi: 10.1007/s00432-015-1987-1.

Becker H, Yoshida K, Blagitko-Dorfs N, Claus R, Pantic M, Abdelkarim M, Niemöller C, Greil C, Hackanson B, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Döhner K, Schnittger S, Henneke P, Niemeyer CM, Flotho C, Pfeifer D, Ogawa S and **Lübbert M.** (2014) Tracing the development of acute myeloid leukemia in *CBL*-syndrome, **Blood** 2014 Mar 20;123:1883-6.

Blagitko-Dorfs N., Jiang Y., Duque-Afonso J., Hiller J., Yalcin A., Greve G., Abdelkarim M., Hackanson B. and **Lübbert M.** (2013) Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat. **PLoS One.** 2013 Oct 8v doi: 10.1371/journal.pone.0075258

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, **Lübbert M.**, ... Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF and Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia, Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. **N Engl J Med** 369, 111-121.

Duque-Afonso, J., Berg, T., Heidenreich, O. and **Lübbert M.** (2011) The HDAC class I specific inhibitor Entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. **Oncogene**

Lübbert, M., Suciu, S., Baila, L., Rüter, B., Platzbecker, U., Giagounidis, A., et al. (2011) Low-dose decitabine vs. Best Supportive Care in elderly patients with intermediate- or high-risk MDS ineligible for intensive chemotherapy: final results of the randomized phase III study of the EORTC Leukemia Group and the German MDS Study Group. **J Clin Oncol** 9, 1987-1996.

Flotho, C., Claus, R., Batz, C., Schneider, M., Sandrock, I., Ihde, S., Plass, C., Niemeyer, C.M. and **Lübbert M.** (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on gene expression in acute myeloid leukemia cells. **Leukemia** 23,1019-1028.

Daskalakis, M., Nguyen, T.T., Nguyen, C., Guldborg, P., Köhler, G., Wijermans, P., Jones, P.A. and **Lübbert, M.** (2002) Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2'-deoxycytidine treatment. **Blood** 100, 2957-2964.